Verve’s Gene Editor Cuts Cholesterol in First-in-Human HeFH Trial

When given at potentially therapeutic doses, Verve’s base editor led to strong reductions in LDL cholesterol and PCSK9 levels in patients with heterozygous familial hypercholesterolemia.